Home "PharmaSource"

Day One - 24 March

Chair: Mike Chace-Ortiz, Sr. Director, Product Strategy, API Intelligence, Thomson Reuters

09:25 – 09:55 Global Pharma Sourcing and Contracting 2010 – The Megatrends

• Reviewing the latest strategic alliance, mergers, acquisition and licensing agreements
• Emerging market sourcing – has it lost its appeal?
• Big Pharma – the new contract manufacturer?
• Evaluating the impact of the rise of the Generics and the implications for Big Pharma sourcing
• Analysing the latest demand trends and the impact on your procurement departments
Johnathon Marshall, Director, Pharmaceutical Operations, PricewaterhouseCoopers
 

09:55 – 10:10 Deal Making – The Life Blood of the Generic Industry – The Megatrends Part II

• What are the key drivers for deal making in the generic industry?
• Deal making as means to ensure access to active ingredients
• Pros and cons of backward integration
• Deal making and generic biologics – what to expect?
Mike Chace-Ortiz, Sr. Director, Product Strategy, API Intelligence, Thomson Reuters
 

10:10 – 10:50 From Tactical to Strategic – The Evolution of Pharma Outsourcing

• Overcoming short-time supply problems – will there always be a role for tactical partners?
• Evaluating the long-term cost advantages and resource management benefits of strategic sourcing
• Efficiently integrating new partners in to your internal manufacturing network
• Can and should tactical partners become strategic partners?
Dr. Michael Herrmann, R&D Outsourcing Manager, International R&D Outsourcing, Nycomed
 

10:50 – 11:30 Big Pharma Insights –  Exploring the Desire to Build Global Supply Bases
• Building & maintaining an effective global supply base
• Strategically consolidating the number of suppliers to create leverage for both parties
• Key strategic requirements for the supply base
• Balancing established and emerging market suppliers to minimise risks to your supply chain
Dr. Kevan Reeve, Global Category Lead, Process Chemicals & Excipients, Global External Sourcing, AstraZeneca
 

11:30 -12:00 Refreshment & Networking

12:00 - 13:00 Roundtables

13:00 – 14:00 Networking Lunch

14:00 – 14:40 Sourcing Criteria and Metrics Used by Big Pharma to Select Their Partners and Suppliers
• What drives Big Pharma to select their partners and suppliers?
• Evaluating the importance of: the speed of project turn around, reputation, and IP protection
• It’s not just about the price – exploring the strategic factors that influence their decision
• Size and capacity – What is the optimum balance?
Dr. James Tornos, Associate Director, Science Services, Outsourcing & Procurement, Pfizer
 

14:40 – 15:20  Achieving Sustainable Chemical Development and Procurement Excellence
• Ensuring the reliable supply of critical raw materials
• Guaranteeing that SHE compliance is achieved when sourcing from emerging markets
• Analysing the selection criteria used to successfully select the right set of suppliers
• Establishing effective communications between development chemists and procurement specialists
John J. Haefele, Global Category Manager Chemicals, Global Strategic Procurement, F. Hoffmann – La Roche  
 

15:20 – 15:50 Refreshment & Networking

15:50 - 16:50 Workshops

16:50-17:00 Chairman’s Closing Remarks

17:00-18:00 Networking Drinks Reception
 

Day Two – 25 March 2010

Chair: Dr. Keith Schlagbauer, Director of Healthcare Consulting, Europe, Frost & Sullivan

09:00 – 09:40 The latest New Supplier Selection Strategies that Minimise Risk
• Reviewing the key factors in the supplier selection process
• Successfully increasing the transparency of your supply chain
• Supplier consolidation – does it decrease risk?
• Supplier consolidation – should it be horizontal or by function?
• Exploring the latest audit procedures and requirements that minimise surprises
Dennis Seagle, Business Director, ICB, Boehringer Ingelheim 

09:40 – 10:20  The ‘Emerging’ Emerging Markets – Where, When and at What Cost?
• Key regional competencies for Pharma manufacturing and API supply outside of India and China
• Comparing the expertise of suppliers and manufactures in Brazil, Russia, Vietnam, Indonesia, Bangladesh, and other markets
• Deal making to take advantage of cost benefits in new markets
• Lessons learned from sourcing from India and China
Mike Chace-Ortiz, Sr. Director, Product Strategy, API Intelligence, Thomson Reuters
 

10:20 – 11:00 Evaluating the Revival of European Manufacturing and API Production
• How does the EU compare to emerging markets? Cost, quality and reliability
• Reviewing the pros and cons of a European supply base
• Charting the re-emergence of the competitive European API suppliers
Dr. Keith Schlagbauer, Director of Healthcare Consulting, Europe, Frost & Sullivan
 

11:00 – 11:30 Refreshment & Networking

12:00 - 13:00 Roundtables

12:30 – 13:30 Networking Lunch

13:30 – 14:10 Protecting the Crown Jewels: Minimising IP Risks When Outsourcing
• Evaluating the key IP risks of outsourcing API development and manufacture
• Formulating an effective IP protection and control strategy
I• ncorporating your IP strategy in contractual arrangements
• Avoiding FTO problems through robust contractual outsourcing agreements
• Enforcing the contract: practical tips on making your IP strategy effective
Christoph de Coster, Attorney in Law & Tim Worden, Partner, Taylor Wessing LLP
 

14:10 – 14.50 An Issue of Quality – How Can You Maintain Standards When Sourcing Globally? 

• Quality assurance systems that guarantee traceability processes and minimise risk
• Evaluating new suppliers ability to meet your supply and quality requirements
• Reviewing the quality and safety issues connected to bulk drug sourcing
Eric Hilton, Director, FDAS – Food & Drug Analytical Services
 

14:50 – 15.20 Refreshment & Networking

15:20 – 16:00 Closing Panel Debate – PharmaSource10 – Any Questions?
• Evaluating the risks – will emerging market sourcing come back to haunt  Big Pharma?
• Are local sourcing centres the key to LCCS success
• What drives Big Pharma to outsource production?
• When should you simply not outsource? Are there sacred cows that must be kept at all costs?
• Can you successfully optimise your value chain and maintain the security of your supply chain?
Speakers: A selection of speakers from across both days of the conference